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Objectives: To examine the effect of neuraminidase (NA) mutations on the NA
inhibitor (NAI) resistance phenotype, the recombinant influenza A/Chungbuk/
4448/2008(H1N1) virus isolated in South Korea during the 2008e2009 season was
generated by reverse genetics.
Methods: Site-directed mutagenesis was introduced on the NA gene of A/
Chungbuk/4448/2008(H1N1) virus, and a total of 23 single, double, and triple
mutants were generated. Resistance phenotype of these recombinant viruses
was determined by NA-inhibition (NAI) assays based on a fluorometric method
using two NAIs (oseltamivir and zanamivir).
Results: NA-inhibition assays showed that all the single and double mutants con-
taining the Y275 except the single Y275-E119V mutant conferred important levels
of resistance to oseltamivir, whereas all the single, double, and triple mutants
containing the E119V mutation were associated with the resistance to zanamivir.
Conclusion: Considering the effect of mutations in NA gene on the resistance to
NAIs, it is important to monitor the possible emergence and dissemination of
multidrug-resistant variants in the human population due to amino acid changes at
NA gene as well as to develop novel NAIs.1. Introduction
Influenza infects approximately 20% of the world’s
population, and more than half a million individuals die
every year of influenza-associated complications [1]. In
2009, the pandemic influenza A(H1N1) virus spreadted under the terms of the C
0) which permits unrestrict
roperly cited.
ase Control and Preventionquickly among humans worldwide to cause the first
influenza pandemic of the 21st century [2].
Vaccination and antiviral treatment are essential for
the prevention and control of influenza infection. With
the use of antiviral drugs for the clinical management of
influenza, neuraminidase (NA) inhibitors (NAIs) havereative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
. Published by Elsevier Korea LLC. All rights reserved.
324 W. Choi, et albeen proved to be very effective against influenza A and
B viruses [3]. However, NAI-resistant strains have been
reported frequently [4,5], in case of the emergence
during the treatment of drug or dissemination of drug-
resistant variants.
Several subtype-specific mutations in framework or
catalytic residues of NA that confer resistance to NAIs
have been reported [1,6e8]. The dominant change
conferring oseltamivir resistance in the current seasonal
influenza viruses is a mutation in the NA gene, H275Y
(N1 numbering). The frequency of isolates with the
H275Y mutation has increased with each flu season,
including in countries where oseltamivir is not pre-
scribed regularly. Particularly, most isolated seasonal
influenza A(H1N1) viruses during the 2008e2009
season were found to encode the H275Y substitution
in the NA gene, conferring resistance to oseltamivir
[9]. Other NA mutations (N2 numbering: E119G,
H274Y, R292K, and N295S) that have been reported
to confer resistance to NAIs were each introduced
into recombinant A/Vietnam/1203/04(H5N1) influenza
virus [10].
Here we selected A/Chungbuk/4448/2008(H1N1)
virus isolated in South Korea during the 2008e2009
season, which was one of the viruses isolated from
throughout the country by the Korean Influenza Sur-
veillance Scheme [11]. To investigate the effect of
different NA mutations on the NAI resistance phenotype
of A/Chungbuk/4448/2008(H1N1) virus, we generated
recombinant A/Chungbuk/4448/2008(H1N1) virus using
a reverse genetics system, introduced the different NA
mutations into the background of the recombinant A/
Chungbuk/4448/2008(H1N1) virus, and compared their
NAI resistance phenotypes.2. Materials and methods
2.1. Cells and viruses
Madin Darby canine kidney (MDCK) cells and
human embryonic kidney cells transformed with large T
antigen (293T cells) were obtained from American Type
Culture Collection (Manassas, VA, USA). A/Chungbuk/
4448/2008(H1N1) virus isolated in South Korea during
the 2008e2009 season was used for the generation of
recombinant viruses.
2.2. Antiviral compounds
Tartrate salt of oseltamivir carboxylate (active form
of Tamiflu) was provided generously by F. Hoffmann-
La Roche, Inc. (Basel, Switzerland); it was dissolved in
distilled water such that the final oseltamivir carboxylate
concentration was 10 mM. Zanamivir (Relenza), which
was provided by GlaxoSmithKline (Stevenage, UK),
was dissolved in distilled water to a final zanamivir
concentration of 10 mM. Aliquots were stored at
20 C until use.2.3. Generation of recombinant viruses and site-
directed mutagenesis
Recombinant viruses were generated using the eight-
plasmid reverse genetics system with pHW2000 (the
vector was provided kindly by Robert Webster, St. Jude
Children’s Research Hospital, Memphis, TN, USA)
[12]. The eight genes from the cultured A/Chungbuk/
4448/2008(H1N1) virus were amplified by reverse
transcription polymerase chain reaction (RT-PCR) and
incorporated into the pHW2000 plasmid. All eight
plasmids were transfected into a coculture of 293T and
MDCK cells for 3 days, and then further prepared in 10-
day-old embryonated chicken eggs. The collected su-
pernatant from the transfected cells was injected into the
allantoic cavities of the eggs and incubated at 37 C for
3 days to amplify the rescued viruses. The viruses
generated in eggs were stored at 80 C until use.
To investigate mutations at NA key residues (N1
numbering: I117V, I117M, E119V, I223V, Y275H,
R293K, N295S, and S334N), site-directed mutagenesis
was conducted on the NA gene cloned plasmid using the
QuickChange Site-Directed Mutagenesis Kit (Stra-
tagene, Santa Clara, CA, USA). All recombinant plas-
mids were sequenced to ensure the absence of undesired
mutations. The eight plasmids were then cotransfected
to 293T mixed with MDCK cells. Supernatants were
collected at 3 days post-transfection and used to inoc-
ulate specific pathogen-free (SPF) eggs. Introduced
mutations of the recombinant wild type virus as well as
the NA mutants were confirmed by sequencing.
2.4. NA activity assay and NA inhibition assay
The NA activity of each virus sample was determined
by a modified fluorometric assay that measured 4-
methylumbelliferone released from the fluorogenic sub-
strate 20-(4-methylumbelliferyl)-a-D-N-acetylneuraminic
acid (MUNANA; Sigma-Aldrich, St. Louis,MO, USA) by
the enzymatic activity of the influenza virus NA [13,14].
The drug resistance phenotype was determined by NA
inhibition assays using the MUNANA (Sigma) substrate,
with minor modifications [13e15]. The viruses were
tested for susceptibility to oseltamivir and zanamivir. To
determine the drug concentration required to inhibit 50%
of the NA activity [50% inhibitory concentration (IC50)],
50 mL of virus, diluted according to the NA activity
assay, was mixed with various concentrations of inhibitor
in microtiter plates (FluoroNunc plates; Nalge Nunc In-
ternational, Penfield, NY, USA). The final reaction
mixture concentration of the NAIs ranged from 0.01 nM
to 10,000 nM. The viruseinhibitor mixture was incu-
bated at room temperature for 45 minutes prior to the
addition of 50 mL of the MUNANA substrate (0.3 mM)
and then incubated at 37 C for 60 minutes. The reaction
was terminated by the addition of 100 mL of the stop
solution. The IC50 for each drug was calculated from the
doseeresponse curve using GraphPad Prism software,
version 5 (San Diego, CA, USA). The sensitive viruses
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mivir and 0.001e25 nM for oseltamivir carboxylate.
The resistant viruses belonged to both inhibitors in the
IC50 range from 43 nM to as high as 8020 nM [15].T
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e.3. Results
3.1. Generation of recombinant wild type and
NA mutant influenza viruses by reverse
genetics system
The recombinant wild-type [A/Chungbuk/4448/
2008(H1N1)] virus was generated by reverse genetics.
That is, the eight genes of A/Chungbuk/4448/
2008(H1N1) virus (PB2, PB1, PA, HA, NP, NA, M, and
NS ) were amplified by RT-PCR (data not shown). The
PCR products were then inserted into pHW2000 vector.
After the cell transfection with these eight plasmids, su-
pernatants were collected at 3 days post-transfection and
used to inoculate SPF eggs. The generation of recombi-
nant wild-type virus was confirmed by sequencing.
We used mutagenesis and plasmid-based reverse
genetics to generate recombinant A/Chungbuk/4448/
2008(H1N1) viruses containing either the wild-type NA
(Y275) or a single amino acid change at NA residue 117
(I/V), 117 (I/M), 119 (E/V), 223 (I/V), 275
(Y/H), 293 (R/K), 295 (N/S), or 334 (S/N). For
example, the recombinant Chungbuk-Y275-I117V virus
contained an I/V amino acid change at residue 117
of NA in the wild-type virus [A/Chungbuk/4448/
2008(H1N1)] and the recombinant Chungbuk-Y275H-
I117V virus contained I/V and Y/H amino acid
changes at residues 117 and 275 of NA in the wild-type
virus, respectively (numbering is based on the N1 NA
protein throughout). Totally, eight single mutants
(Y275-I117V, Y275-I117M, Y275-E119V, Y275-
I223V, Y275H, Y275-R293K, Y275-N295S, and
Y275-S334N), 10 double mutants (Y275H-I117V,
Y275H-I117M, Y275H-E119V, Y275H-I223V, Y275H-
R293K, Y275H-N295S, Y275H-S334N, Y275-N295S-
I117V, Y275-N295S-I117M, and Y275-N295S-I223V),
and five triple mutants (Y275H-E119V-I117V, Y275H-
E119V-I117M, Y275H-N295S-I117V, Y275H-N295S-
I117M, and Y275H-N295S-I223V) were generated
(Table 1). Introduced mutations of the recombinant NA
mutants were confirmed by sequencing.
3.2. Susceptibility of recombinant wild-type
and NA mutant influenza viruses to NAIs
in vitro
An enzymatic NA inhibition assay was used to
characterize the susceptibilities of recombinant A/
Chungbuk/4448/2008(H1N1) virus and each of the 23
mutants to oseltamivir and zanamivir (Table 2). NA-
inhibition assays showed that E119V mutation of the
wild-type virus containing tyrosine (Y) at NA residue
275 (Chungbuk-Y275-E119V) and E119V mutation of
Table 2. Susceptibility of the recombinant influenza A(H1N1) viruses to NAIs.
Recombinant virus
Neuraminidase inhibition assay
Oseltamivir Zanamivir
Mean IC50  SD (nM)a Fold changeb Mean IC50  SD (nM)a Fold changeb
Chungbuk-Y275H 1.1  0.5 1.0 2.0  0.6 1.0
Chungbuk-Y275H-I117V 2.0  0.4 1.8 1.1  0.4 0.5
Chungbuk-Y275H-I117M 0.4  0.1 0.4 0.4  0.1 0.2
Chungbuk-Y275H-E119V 16.9  2.0 15.4 271.5  17.7 135.7
Chungbuk-Y275H-I223V 1.9  0.2 1.7 0.6  0.4 0.3
Chungbuk-Y275H-R293K 0.6  0.1 0.5 35.7  6.3 17.8
Chungbuk-Y275H-N295S 44.3  7.0 40.2 2.2  1.0 1.1
Chungbuk-Y275H-S334N 0.7  0.1 0.6 0.4  0.1 0.2
Chungbuk-Y275H-E119V-I117V 7.4  0.4 6.7 781.3  39.5 390.6
Chungbuk-Y275H-E119V-I117M 21.5  2.2 19.5 362.0  22.0 181.0
Chungbuk-Y275H-N295S-I117V 66.1  13.5 60.0 4.0  1.0 2.0
Chungbuk-Y275H-N295S-I117M 57.7  17.2 52.4 7.5  2.2 3.7
Chungbuk-Y275H-N295S-I223V 107.2  8.3 97.4 3.1  0.4 1.5
Chungbuk-Y275 552.4  67.6 1.0 1.3  0.9 1.0
Chungbuk-Y275-I117V 751.8  51.1 1.3 1.0  0.4 0.7
Chungbuk-Y275-I117M 434.8  12.6 0.7 0.8  0.2 0.6
Chungbuk-Y275-E119V 23.4  2.4 0.04 263.3  47.3 202.5
Chungbuk-Y275-I223V 642.8  24.0 1.1 0.7  0.2 0.5
Chungbuk-Y275-R293K 557.5  12.8 1.0 2.2  0.4 1.6
Chungbuk-Y275-N295S 118.9  20.0 0.2 2.4  0.4 1.8
Chungbuk-Y275-S334N 456.7  38.2 0.8 0.6  0.2 0.4
Chungbuk-Y275-N295S-I117V 369.6  40.5 0.6 34.8  10.8 26.7
Chungbuk-Y275-N295S-I117M 133.2  12.5 0.2 21.3  5.0 16.3
Chungbuk-Y275-N295S-I223V 330.4  55.1 0.5 26.3  7.7 20.2
aAverage of three independent assays (fluorometric NA inhibition assay); bFold difference in IC50 values between mutants and wild-type (Chungbuk-Y275) or
mutants and Chungbuk-Y275H, by drug. IC50 Z 50% inhibitory concentration; NA Z neuraminidase; NAI Z neuraminidase inhibitor; SD Z standard
deviation of IC50 values.
326 W. Choi, et althe mutant virus containing histidine (H) at NA residue
275 (Chungbuk-Y275H-E119V) conferred important
levels of resistance to zanamivir, with 202.5-fold and
135.7-fold increases in IC50 values compared with that
of the wild-type virus (Chungbuk-Y275) and Chungbuk-
Y275H mutant virus, respectively, whereas these mu-
tants were susceptible to oseltamivir. Compared with the
single Chungbuk-Y274H mutant, triple Chungbuk-
Y275H-E119V-I117V and Y275H-E119V-I117M mu-
tants had increased IC50 values for zanamivir (390.7-
and 181.0-fold), whereas these mutants were susceptible
to oseltamivir. All the single, double, and triple mutants
containing the E119V mutation were associated with the
resistance to zanamivir.
All the single and double mutants containing tyrosine
(Y) at NA residue 275 of the wild-type virus except
the single mutant (Chungbuk-Y275-E119V) conferred
important levels of resistance to oseltamivir, whereas
the wild-type virus and these mutants were associated
with the susceptibility to zanamivir.
The N295S mutation in the wild-type virus (Chung-
buk-Y275-N295S) was associated with a reduction in
oseltamivir resistance (0.2-fold decrease in IC50
compared with that of the wild-type virus), whereas
N295S mutation of the mutant virus containing histidine(H) at NA residue 275 (Chungbuk-Y275H-N295S) was
associated with an increase in oseltamivir resistance
(40.3-fold increase in IC50 compared with that of
Chungbuk-Y275H mutant virus). Compared with the
single Chungbuk-Y274-N295S mutant, double Chung-
buk-Y275-N295S-I117V, Y275-N295S-I117M, and
Y275-N295S-I223V mutants had slightly increased IC50
values for oseltamivir (3.1-fold, 1.1-fold, and 2.8-fold),
whereas these mutants were susceptible to zanamivir.
Compared with the double Chungbuk-Y274H-N295S
mutant, triple Chungbuk-Y275H-N295S-I117V, Y275H-
N295S-I117M, and Y275H-N295S-I223V mutants also
had slightly increased IC50 values for oseltamivir (1.5-
fold, 1.3-fold, and 2.4-fold), whereas these mutants
were susceptible to zanamivir.
The single I117V, I117M, I223V, R293K, N295S, or
S334N mutation did not seem to contribute significantly
to a phenotype resistant to oseltamivir as well as to
zanamivir.4. Discussion
Although many subtype-specific NA mutations
conferring resistance to NAIs in influenza A(H1N1),
Effect of NA mutations on NAI resistance phenotype 327A(H3N2), and A(H5N1) viruses have been reported
previously [1,4e8,10,16e18], differences in viral
backgrounds can account for a differential effect of
these mutations on antiviral resistance or viral fitness.
Hence, we generated a recombinant wild-type
A(H1N1) virus and its 23 mutants using a reverse ge-
netics system to examine the effect of NA mutations on
the NAI resistance phenotype. We used A/Chungbuk/
4448/2008(H1N1) virus, which was isolated in South
Korea during the 2008e2009 season as a wild-type
virus.
NA-inhibition assays showed that all the single and
double mutants containing the Y275, except the single
Y275-E119V mutant, conferred important levels of
resistance to oseltamivir, whereas all the single, double,
and triple mutants containing the E119V mutation were
associated with the resistance to zanamivir (Table 2).
In combination with Y275, the I117V or I223V
mutation has a synergistic effect on oseltamivir resis-
tance, increasing IC50 values of oseltamivir by 1.3-fold
and 1.1-fold, respectively, compared to the values
caused by the Y275 mutation alone. Addition of the
N295S mutation to the Y275H mutation has a syner-
gistic effect on oseltamivir resistance, increasing the
IC50 value of oseltamivir to 40.3-fold of that of the
Y275H mutation alone, whereas the addition of the
N295S mutation to the Y275 has an antagonistic effect
on oseltamivir resistance, decreasing the IC50 value of
oseltamivir to 0.2-fold of that of the Y275 alone.
The I117M mutation was detected in a pandemic
(H1N1) 2009 virus from South Korea that was isolated
from a patient during oseltamivir treatment [19]. The
I117V mutation was detected in influenza A(H5N1)
virus [20]. A previous study has reported that I117V has
a synergistic effect of increasing resistance with H275Y,
whereas the I117M mutation does not alter oseltamivir
sensitivity in the recombinant viruses with NA from the
pandemic (H1N1) 2009 virus and the remaining genes
from A/PR/8/34 [21]. In this study, we had similar re-
sults in case of the recombinant A/Chungbuk/4448/
2008(H1N1) virus.
In summary, I117V or I223V mutation has increased
the resistance to oseltamivir in combination with Y275
virus, whereas N295S mutation has decreased resistance
to oseltamivir in combination with Y275 virus. Different
amino acid substitutions at key NA residues can cause
considerably different effects on NAI susceptibility.
Here, we showed the NA activities of recombinant
wild-type and NA mutant influenza viruses to NAIs
in vitro. Further in vivo and clinical studies are required
to investigate the effect of these drug-resistant mutants.
Considering the effect of mutations in NA gene on the
resistance to NAIs, it is important to monitor the
possible emergence and dissemination of multidrug-
resistant variants in the human population due to
amino acid changes at NA gene as well as the to develop
novel NAIs.Acknowledgments
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